Clinical trial NCT01243073: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Official title: A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Essential Thrombocythemia
Polycythemia Vera
Keywords: imetelstat
imetelstat sodium
GRN163L
telomerase inhibitor
telomerase
essential thrombocytosis
essential thrombocythemia
ET
polycythemia vera
PV
Lead sponsor: Geron Corporation
Sponsor class: INDUSTRY
First posted: 2010-11-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase II open-label study of single agent imetelstat in patients with essential thrombocytopenia or with polycythemia vera who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy.

Detailed description: For patients with ET: To obtain a preliminary estimate of efficacy of imetelstat, as measured by best hematologic response within the first year of therapy in patients with ET who have failed or are intolerant to at least one prior therapy, or who have refused standard therapy.

For patients with PV: To obtain a preliminary estimate of efficacy of imetelstat, as measured by maintenance of Hct \< 45% in men and \< 42% in women (or pre-specified Hct count that is tolerable) without phlebotomy or myelosuppressive therapy within the first year of therapy in patients with PV who have failed or are intolerant to at least one prior therapy, or who have refused standard therapy.

Eligibility criteria: Inclusion Criteria:

ET-Specific Criteria

* Confirmed diagnosis of ET by WHO criteria
* Patients with ET requiring cytoreduction who have failed or are intolerant to at least one prior therapy, or who refuse standard therapy
* Laboratory criteria (within 14 days of first study drug administration):

  * Platelets \> 600,000/μL
  * ANC ≥ 1500/μL
  * Hemoglobin ≥ 10 g/dL

PV-Specific Criteria

* Confirmed diagnosis of PV by WHO criteria
* Patients with PV requiring cytoreduction with phlebotomy and/or myelosuppressive agents

  * Patients may have failed or are intolerant to at least one prior therapy, or refuse standard therapy
  * For those patients receiving phlebotomy only, the frequency over the past year must be at least one phlebotomy every 3 months.
* Undergone phlebotomy and attained a Hct \< 47% (men) or \< 45% (women) (or pre-specified Hct count that is tolerable) within 14 days prior to the start of study treatment
* Cessation of myelosuppressive agents prior to initiation of study treatment (unless approved by Geron Medical Monitor for unusual circumstances)

  * Hydroxyurea or anagrelide: Cessation 1 day prior to initiation of study treatment. Consideration to the timing of cessation of this therapy prior to the start of study treatment should take into account the requirement for phlebotomy.
  * INF-α or pegylated- INF-α: Cessation 4 weeks prior to initiation of study treatment
* Laboratory criteria (within 14 days of first study drug administration):

  * Platelets \> the lower limit of normal (LLN)
  * ANC ≥ 1500/μL

General Criteria (All Patients)

* Willing and able to sign an informed consent
* Male or female, aged 18 years or older
* ECOG performance status 0-2
* Laboratory criteria (within 14 days of first study drug administration):

  * INR (or PT) and aPTT \< 1.5 x the upper limit of normal (ULN)
  * Serum creatinine ≤ 2 mg/dL
  * Serum bilirubin \< 2.0 mg/dL (patients with Gilbert's syndrome: serum bilirubin \< 3 x ULN)
  * AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN
  * Alkaline phosphatase \< 2.5 x ULN
* Any clinically significant toxicity from previous cancer treatments and/or major surgery must have recovered to Grade 0-1 prior to initiation of study treatment
* Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during and for at least 12 weeks after the last study treatment with imetelstat
* Male patients must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last study treatment with imetelstat.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from screening and study entry:

* Women who are pregnant or breast feeding
* Prior stem cell transplantation
* Investigational therapy within 4 weeks prior to first study drug administration
* Clinically significant cardiovascular disease or condition including:

  * Uncontrolled congestive heart failure (CHF)
  * Need for anti-arrhythmic therapy for a ventricular arrhythmia
  * Clinically significant severe conduction disturbance per the Investigator's discretion
  * Ongoing angina pectoris requiring therapy
  * New York Heart Association (NYHA) Class II, III, or IV cardiovascular disease (see Appendix E)
* Known positive serology for human immunodeficiency virus (HIV)
* Serious co-morbid medical conditions, including active or chronically recurrent bleeding, clinically relevant active infection, cirrhosis, and chronic obstructive or chronic restrictive pulmonary disease per the Investigator's discretion
* Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.

Primary outcomes:
measure: Hematologic Response
timeFrame: From time of first dose (cycle 1 day 1) through end of study (12 mos after last participant is dosed)
Secondary outcomes:
measure: Safety and tolerability: Number of Patients with Hematological Toxicities, Non-Heme Grade 3 and 4 AEs, and Hemorrhagic Events
timeFrame: From time of first dose (cycle 1 day 1) through end of study (12 mos after last paricipant is dosed)
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: Orlando
country: United States
facility: MDACC - Orlando
state: Florida
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Baltimore
country: United States
facility: Johns Hopkins University - Bunting Blaustein Cancer Research Building
state: Maryland
city: Greenville
country: United States
facility: Saint Francis Hospital
state: South Carolina
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Essen
country: Germany
facility: University Hospital of Essen - West German Cancer Center
city: Frankfurt
country: Germany
facility: Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität
city: Heilbronn
country: Germany
facility: SLK-Kliniken GmbH
city: Munich
country: Germany
facility: Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School
city: Regensburg
country: Germany
facility: University Hospital Regensburg - Uniklinik Regensburg
city: Bern
country: Switzerland
facility: INSELSPITAL, University Hospital Bern
Study officials:
References:
citation: Oppliger Leibundgut E, Haubitz M, Burington B, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, Snyder DS, Baerlocher GM. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica. 2021 Sep 1;106(9):2397-2404. doi: 10.3324/haematol.2020.252817.
citation: Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Roth A, Daskalakis M, Burington B, Stuart M, Snyder DS. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.